BioVie

We are developing and commercializing BIV201, a Phase 2a Orphan drug candidate for the treatment of ascites due to chronic liver cirrhosis.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chicago, IL, US
  • Currency USD
  • Founded April 2013
  • Employees 5
  • Incorporation Type C-corp
  • Website biovieinc.com

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free